REG - Destiny Pharma PLC - Exercise of Options and Total Voting Rights

Destiny PharmaAnnouncement

19/03/2024 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240319:nRSS4700Ha&default-theme=true

RNS Number : 4700H  Destiny Pharma PLC  19 March 2024

Destiny Pharma plc

("Destiny Pharma" or the "Company")

 

Exercise of Options and Total Voting Rights

 

Brighton, United Kingdom - 19 March 2024 - Destiny Pharma (AIM: DEST), a
clinical stage biotechnology company focused on the development and
commercialisation of novel medicines to prevent and cure life threatening
infections, announces that it has issued and allotted 40,000 new ordinary
shares of 1 pence each in the capital of the Company (the "New Ordinary
Shares") following an exercise of share options by a former employee.

Application will be made to the London Stock Exchange for the New Ordinary
Shares to be admitted to trading on AIM, with dealings expected to commence on
25 March 2024 ("Admission").

Following Admission, the Company will have a total of 95,311,863 Ordinary
Shares in issue. Shareholders may use this figure of 95,311,863 Ordinary
Shares as the denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their interest
in, the share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

- END -

 

For further information, please contact:

 

Destiny Pharma plc
Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440
pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

FTI Consulting

Ben Atwell / Simon Conway

+44 (0) 203 727 1000

 

Shore Capital (Nominated Adviser and Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

About Destiny Pharma

 

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The company's drug development pipeline includes
two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US, and XF-73 nasal gel, a
proprietary drug targeting the prevention of post-surgical staphylococcal
hospital infections including MRSA.

 

 

For further information on the company, please visit www.destinypharma.com
(https://url.avanan.click/v2/___http:/www.destinypharma.com___.YXAxZTpzaG9yZWNhcDphOm86NDFiY2U5NzMxYmQ5MGJiNTAwMjAxMzI3ODA0Mjg3N2E6NjplZTk4OmI4ZGI1NTY1NmFhMzA4Nzg3NDVlODliNTQ2ZDQ1ZWE5MGVjMWYwYTM5NTIzYjExZDMxODJmMWFkZTVmM2ZkODI6cDpG)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFSSVEIALIS